GaBI Journal publishes four issues in 2013
Suggested evaluation of biological drugs role for WHO – Editor’s response
Critical immunogenicity differences will be obscured by a common INN for biosimilars
WHO leadership in public safety on biosimilars to be commended
Biosimilars naming and prescribing policy in Australia
Maximizing quality in the manufacture of biologicals
Establishment of reference standards in biosimilar studies
Immunogenicity of biosimilar monoclonal antibodies
Biosimilar development and regulation in Japan
Source URL: https://gabi-journal.net/20134-gabi-journal-table-of-contents.html
Copyright ©2024 GaBI Journal unless otherwise noted.